During Q3FY25, we launched 20 new products across countries, with the year-to-date total to 59. Pharmaceutical Services and Active Ingredients (PSAI) Income Statement Highlights: Gross Margin Selling, General & Administrative (SG&A) Expenses Research & Development (R&D) Expenses Net Finance Income Income Tax - the reversal of a previously recognized deferred tax asset on indexation of land; - change in the mix of tax jurisdictions; and - the recognition of a previously unrecognized deferred tax asset on operating tax losses, primarily pertaining to Dr. Reddy's Laboratories SA, Switzerland, during the nine months ended December 31, 2023. Profit before tax Profit attributable to Equity Holders of Parent Company Diluted Earnings per Share (EPS) Other Highlights: Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) Others: About key metrics and non-GAAP Financial Measures This press release contains non-GAAP financial measures within the meaning of Regulation G and Item 10(e) of Regulation S-K.